Evoke製藥 EVOK 深 滬
已收盤 12-12 16:00:00 美东时间
10.95
0.000
0.00%
華盛通- 最 高10.99
- 今 開10.97
- 成交量 8.32万股
- 最 低 10.95
- 昨 收 10.95
- 總市值 1706.56万
- 52周最高 10.99
- 市盈率 靜 --
- 換手率 5.34%
- 52周最低 1.94
- 委 比 -21.56%
- 總股本 155.85万
- 歷史最高 2052.00
- 量 比 4.11
- 振 幅 0.37%
- 歷史最低 1.94
- 每 手 1
- 風險率 2.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-HBAN, AVDL, EVOK, and TRUE
NEW YORK, Nov. 13, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholder...
11-14 06:30
Evoke Pharma Q3 EPS $(0.45), Inline, Sales $4.284M Miss $4.326M Estimate
Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.45) per share which met the analyst consensus estimate. This is a 52.13 percent increase over losses of $(0.94) per share from the same period last year. The
11-13 20:14
Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Evoke Pharma reported a 61% year-over-year increase in third-quarter 2025 net product sales to $4.3 million. The company has entered into an agreement to be acquired by QOL Medical for $11.00 per share in cash. Additionally, the patent for Gimoti, its nasal spray for diabetic gastroparesis, has been extended to November 2038. Despite higher expenses, the company remains focused on growth and expanded distribution. The tender offer for the acquisi...
11-13 12:00
What's Going On With IPG Photonics Stock Tuesday?
IPG Photonics Corp. (NASDAQ: IPGP) reported Q3 results beating expectations with 35 cents/share earnings and $250.79 million sales.
11-05 04:26
Evoke Pharma Rockets On Grabbing 140% Premium In Acquisition Deal
Evoke Pharma surges after QOL Medical announces $11 cash acquisition, a 140% premium, expected to close by the end of 2025.
11-04 23:20
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Evoke Pharma (NASDAQ:EVOK) shares moved upwards by 134.4% to $10.76 dur...
11-04 20:06
快讯 | Evoke Pharma Inc：提议的交易为每股11.00美元现金在收盘时支付
Evoke Pharma Inc: Proposed Deal for for $11.00 per Share in Cash at Closing
11-04 20:01
Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical
QOL Medical to acquire Evoke Pharma for $11.00 per share in cash, representing a 139.7% premium to Evoke's recent stock price. The deal, expected to close by late 2025, values Evoke's GIMOTI treatment for diabetic gastroparesis. Evoke and QOL Medical CEOs highlight strategic alignment and mutual benefits, with QOL Medical bringing commercial expertise to expand GIMOTI's reach. The transaction, approved by both boards, is financed with QOL Medical...
11-04 12:00
J.P. Morgan Keeps Their Hold Rating on 888 Holdings (EVOK)
J.P. Morgan analyst Karan Puri maintained a Hold rating on 888 Holdings yesterd...
10-29 20:25
Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship
Evoke Pharma announced partnerships with Omnicell and Brentwood Pharmacy to expand access to GIMOTI, the only FDA-approved nasal spray for diabetic gastroparesis. These collaborations aim to enhance distribution through specialty pharmacies, nearly doubling the network and improving patient access. GIMOTI addresses a serious GI disorder affecting millions, offering relief via metoclopramide in a nasal spray form. The agreements with Omnicell and ...
08-26 11:00
